Taiwan’s MegaPro Biomedical Co (巨生生醫) and China Chemical & Pharmaceutical Co (CCPC, 中國化學製藥) yesterday announced that they have set up a joint venture with China’s Wellbridge Biotech Ltd (蘇州瑋琪) focusing on the development of drugs in inhalation dosage forms.
MegaPro said it would invest about US$600,000 for a 30 percent stake in the joint venture — Trium Therapeutics Co — while CCPC and Wellbridge would hold 40 percent and 30 percent respectively.
Trium’s chairman and general manager are to be appointed by CCPC and MegaPro respectively, it said.
Photo: Grace Hung, Taipei Times
Trium’s main research goal is to meet pharmaceutical companies’ demand for non-invasive routes of drug administration, such as via the nasal cavity, to improve patients’ comfort and drugs’ bioavailability, MegaPro said.
MegaPro would utilize its expertise in improving drug delivery technology and develop new dosage forms on its nano-platform technology, it said.
MegaPro would also be responsible for conducting animal tests and human trials, it added.
CCPC, which operates Good Manufacturing Practice-certified pharmaceutical plants, as well as sales channels at home and abroad, would be responsible for mass production and marketing, while Wellbridge, which specializes in medical nebulizers, would provide technical information for the development of inhalation dosage forms and supply nebulizer equipment, the companies said.
“Oral dosage forms have been well-developed and widely used by generic drug manufacturing pharmaceutical companies. How to expand special treatment pathways has become the next phase of development in the pharmaceutical industry,” CCPC general manager Wu Zhi-yong (吳志庸) said in a statement.
Reports by Data Bridge Market Research Private Ltd, a professional research company, show that the global market for inhalers is expected to reach US$42.1 billion in 2027, with a compound annual growth rate of 5.87 percent from this year to 2027, MegaPro said.
As patients inhale the drug, its main components can be quickly absorbed by the lungs and dense blood capillaries, it said.
Trium has completed the screening of drug candidates and the preliminary animal tests, and would carry out stability tests and more animal tests, the companies said.
Spun off in 2014 from the Industrial Technology Research Institute, MegaPro focuses on developing niche nano-medicines and holds two proprietary nanotechnology platforms, with three product pipelines treating iron deficiency anemia and hepatocellular carcinoma.
MegaPro reported zero revenue for the first half of this year, while CCPC’s revenue was flat from a year earlier at NT$4.03 billion (US$135.2 million), companies’ data showed.
Cairo’s new monorail slices across the city skyline, running above the familiar chaos of blaring horns and aging buses’ exhaust fumes that mark rush hour below. The US$4.5 billion monorail, opened this month, is among Egypt’s most prominent new transport projects, part of a debt-funded infrastructure drive criticized for sapping state finances while bringing limited benefits to most of the country’s 109 million people. “It feels like you’re in a different country,” said Ramy Sayed, a restaurant manager, aboard a driverless Innovia 300 train. “No noise, no traffic, we’re not used to this.” The eastern line runs 56km from the bustling middle-class
Taiwanese firms have increased investment in the Philippines in recent years as Manila’s ties with Washington deepen and global supply chains continue to shift away from China, an expert at the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The Philippines had not been among Taiwanese investors’ top choices in Southeast Asia, CIER Taiwan ASEAN Studies Center director Kristy Hsu (徐遵慈) said at a seminar in Taipei. However, Taiwan’s investment in the country has grown significantly since the COVID-19 pandemic, reaching US $257 million last year, a high in recent years, she said. Although Taiwan’s total investment in the Philippines still lags
Starlux Airlines Co (星宇航空) today unveiled a long-haul network expansion plan at a shareholders’ meeting in Taipei, including direct flights to Barcelona, Spain, and Zurich, Switzerland, as well as a service connecting Taipei, Sydney and New Zealand. Starlux is to become the first Taiwanese carrier to offer non-stop services to the two European cities, while the inaugural oceanic route is expected to expand transit opportunities within the Australia-New Zealand market, Starlux said. Flight services to Chicago, Dallas, Washington and New York are under evaluation, the airline added. Prior to the shareholders’ meeting, the airline earlier this year announced that it would be
Intel Corp regards Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) as a longstanding partner, as the US chipmaker would continue outsourcing production of advanced chips to TSMC, Intel chief executive officer Lip-Bu Tan (陳立武) said yesterday. “I don’t look at people as competitors. I look at the collaboration... Nvidia is also, you know, a good friend,” Tan told a news conference following his keynote speech at the Computex trade show in Taipei. “It’s a very trusted partnership for us... We are a big, top customer for them, and we’re going to continue doing that,” he said, referring to TSMC, the world’s largest foundry
RSS